Lisa Lancaster MD
Critical Care Medicine, Interstitial Lung Diseases, Sleep Medicine
Professor, Medicine, Vanderbilt University School of Medicine
Join to view full profile
3601 21st Ave SNashville, TN 37232
Phone+1 615-322-3000
Dr. Lancaster is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Lisa Lancaster is a pulmonologist in Nashville, TN and is affiliated with Vanderbilt University Medical Center. She received her medical degree from Medical College of Georgia School of Medicine and has been in practice 24 years. She specializes in pulmonary medicine, interstitial lung disease, idiopathic pulmonary fibrosis, and sleep medicine and is experienced in transplant pulmonology, cystic fibrosis, and ILD clinical trials.
Education & Training
University of Alabama Hospital (Birmingham)Residency, Pulmonary Disease and Critical Care Medicine, 2019 - 2025
Vanderbilt University Medical CenterFellowship, Pulmonary Disease and Critical Care Medicine, 1996 - 1999
University of Tennessee College of Medicine (Nashville)Residency, Internal Medicine, 1993 - 1996
Medical College of Georgia at Augusta UniversityClass of 1993
Certifications & Licensure
TN State Medical License 1996 - 2027
AL State Medical License 2020 - 2020
American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification StarPanel, Vanderbilt University, 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification StarPanel, Vanderbilt University, 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification BI-Clinical, CitiusTech, Inc., 2012, 2014-2017
Clinical Trials
- STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2012 Jul 16
- Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2013 Jan 31
- Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2013 Jul 30
Publications & Presentations
PubMed
- When symptoms and resting tests disagree in interstitial lung disease: a selective role for cardiopulmonary exercise testing.Bathmapriya Balakrishnan, Daniel A Culver, Lisa H Lancaster, Adriano R Tonelli, Jeffrey J Swigris
The European Respiratory Journal. 2026-08-01 - Beyond Rest-Based Staging in Interstitial Lung Disease: Where Cardiopulmonary Exercise Testing Adds Value.Bathmapriya Balakrishnan, Daniel A Culver, Lisa H Lancaster, Adriano R Tonelli, Jeffrey J Swigris
Annals of the American Thoracic Society. 2026-04-16 - 5 citationsBexotegrast for treatment of idiopathic pulmonary fibrosis (BEACON-IPF): study protocol for a multinational, phase 2b/3, double-blind, randomised, multicentre, control...Wim A Wuyts, Lisa Lancaster, Toby M Maher, Christopher J Ryerson, Michael Kreuter
BMJ Open Respiratory Research. 2026-03-10
Press Mentions
PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)May 9th, 2025- Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast Was Well Tolerated at 320 Mg with Durable Improvement Shown in FVC and Across Multiple MeasuresApril 30th, 2023
- Highest Dose Bexotegrast Found to Improve Lung Function in IPFJanuary 31st, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: